青少年1型糖尿病筛查项目的临床实践证据
1型糖尿病在症状出现前呈连续进展阶段,筛查胰岛自身抗体在高危儿童及一般人群中日益常见。筛查主要目标是减少诊断时糖尿病酮症酸中毒(DKA)并参与延缓临床发病的研究方案,但需权衡心理症状与成本。本文介绍意大利实施该证据的实践经验。
要点
- 筛查胰岛自身抗体可识别症状前1型糖尿病阶段,主要目标是降低诊断时DKA发生率。
- 筛查阳性者的监测频率和强度取决于年龄及检出自身抗体数量,并决定是否转诊专科。
- 基层儿科医生可负责家庭入组和毛细血管采血,将筛查整合入常规儿科诊疗。
核心结论
- 对高危儿童及一般人群筛查胰岛自身抗体有助于在症状前识别1型糖尿病,主要目标是减少诊断时DKA并参与延缓临床发病的研究方案。
研究设计与样本
- 本文为综述,描述1型糖尿病筛查项目的证据及在意大利的临床实施经验。
主要发现
- 1型糖尿病在症状出现前呈连续进展,经历可识别的不同阶段。
- 筛查的主要优势需与健康儿童青少年及家长可能出现的焦虑、抑郁等心理症状及筛查成本进行平衡。
- 一般人群筛查的最佳年龄已由多项研究的队列分析确立。
关键数值与推荐
- 筛查阳性者的监测频率和强度受年龄及检出自身抗体数量影响,并决定是否转诊专科中心。
- 监测措施包括胰岛自身抗体、糖化血红蛋白、随机血糖、口服葡萄糖耐量试验(OGTT)和持续葡萄糖监测(CGM)。
临床怎么用
- 基层医生可负责家庭入组和一般人群的毛细血管血采样。
- 根据筛查阳性者的年龄和自身抗体数量决定监测频率、强度及是否转诊专科。
- 可参考意大利经验将筛查整合入常规儿科诊疗。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Studies of individuals at risk for developing type 1 diabetes (T1D) have demonstrated that the disease is a continuum that progresses sequentially through distinct identifiable stages before the onset of symptoms. Screening for islet antibodies (IAbs) in at-risk children for T1D (first-degree relatives or those with human leukocyte antigen genetic risk) and in the general population is becoming increasingly common in some countries. The main aim of the T1D screening program is to reduce rates of diabetic ketoacidosis (DKA) at diagnosis and to participate in research protocols that receive T1D-modifying therapies to delay clinical onset. These advantages are generally balanced with the psychological symptoms (such as anxiety and depression) that this information could produce in healthy children-adolescents and their parents, and the costs of the screening. Optimal ages for performing IAb screening in the general population have been established by cohort analyses in several studies. Primary care physicians can be responsible for family enrollment and capillary blood sampling in the general population. For follow-up of individuals who screen positive for IAbs, both age and the number of IAbs detected influence how frequently and intensively monitoring is recommended, as well as whether referral to a specialist care center is advised. Measures considered for monitoring include IAbs, hemoglobin A1c, random blood glucose, oral glucose tolerance test (OGTT), and continuous glucose monitoring (CGM). This article describes how such evidence has been implemented in Italy, offering practical insights into integrating screening into routine pediatric care.
引用
- Franceschi R, Mozzillo E, Marigliano M, et al. Screening Programs for Type 1 Diabetes in Youth: Evidence for Clinical Practice. Pediatrics. 2026. PMID: 42134804. doi:10.1542/peds.2025-075728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。